Who Owns Axsome Company?

Axsome Bundle

Get Full Bundle:

	SWOT	$15	$10
	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10

TOTAL:

ADD TO CART

Who Really Owns Axsome Therapeutics?

Understanding the ownership structure of Axsome SWOT Analysis is crucial for investors and analysts alike. Axsome Therapeutics, a biopharmaceutical company focused on central nervous system (CNS) disorders, has seen its ownership evolve since its IPO in November 2015. This evolution reflects the company's strategic direction and its ability to navigate the complex pharmaceutical landscape. Discover who the major shareholders of Axsome are and how they influence its future.

From its founders to its current institutional investors, Axsome's ownership tells a story of growth and strategic alignment. Examining the company's shareholder information, including Axsome executives and major stakeholders, provides valuable insights. The company's market capitalization and annual revenue are directly impacted by the decisions of its owners. This analysis aims to uncover the key players shaping the future of Axsome Pharmaceuticals, including its product pipeline and leadership team.

The genesis of Axsome Therapeutics began in January 2012 with its founding by Herriot Tabuteau, M.D., who currently holds the positions of Chairman and Chief Executive Officer. His vision was instrumental in shaping the company's focus on central nervous system (CNS) disorders.

Early ownership was significantly influenced by Dr. Tabuteau and Antecip Capital LLC (formerly Versant Capital Management LLC), where Dr. Tabuteau is the founder and managing member. Antecip played a crucial role in the initial capitalization of Axsome.

The company's journey continued with an Initial Public Offering (IPO) on the NASDAQ exchange in November 2015, which was a pivotal moment for Axsome Therapeutics, providing the necessary capital to advance its clinical pipeline and solidify its position in the pharmaceuticals sector.

Founding

Founded in January 2012.

Founder

Herriot Tabuteau, M.D., Chairman and CEO.

Early Investor

Antecip Capital LLC (formerly Versant Capital Management LLC), with Dr. Tabuteau as founder and managing member, was a principal stockholder.

Initial Stock Issuance

Antecip was issued 7,344,500 shares of common stock in connection with Axsome's formation.

IPO

IPO in November 2015, priced at $9.00 per share.

IPO Proceeds

Raised approximately $57.5 million in gross proceeds.

Key Takeaways

The early ownership structure of Axsome Therapeutics, with Dr. Tabuteau and Antecip Capital as significant stakeholders, reflects a strategic vision focused on CNS disorders. The IPO in 2015 was a crucial step, providing capital for the advancement of its clinical pipeline. For more insights into the company's strategic direction, consider reading about the Target Market of Axsome.

• Herriot Tabuteau, M.D., founded Axsome Therapeutics in January 2012.
• Antecip Capital LLC, where Dr. Tabuteau is the founder and managing member, was a principal stockholder.
• The IPO in November 2015 raised approximately $57.5 million.
• Dr. Tabuteau's convertible note converted into 7,229 shares during the IPO.

Axsome SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Since its initial public offering (IPO) in November 2015, the ownership structure of Axsome Therapeutics has shifted significantly. This evolution has seen a move towards greater institutional ownership. As of May 31, 2025, institutional investors held a substantial 77.76% of the total outstanding shares. This indicates a strong level of confidence from large financial entities in the company's future. As of June 13, 2025, 646 institutional owners and shareholders, having filed 13D/G or 13F forms with the SEC, collectively held 44,242,302 shares.

In April 2025, institutional ownership was reported at 75.40%. Mutual funds have also increased their holdings, rising from 46.02% to 46.43%. This trend reflects the company's growth and its increasing appeal to institutional investors. The shift highlights the transition of Axsome Therapeutics into a biopharmaceutical entity, with large financial entities showing faith in its growth trajectory. These shifts are important for understanding the dynamics of Axsome ownership and its impact on the company's strategic direction.

Key institutional shareholders as of late 2024 and early 2025 include Vanguard Group Inc., BlackRock, Inc., and RTW Investments, LP. Vanguard Group Inc. held the most shares, with 3,761,007 shares as of May 2025, representing 7.64% ownership. RTW Investments held 2,923,000 shares, representing 5.92% ownership as of June 3, 2025. Individual insiders, including executives and directors, hold a smaller but significant portion of the company's stock. As of April 2025, insider ownership was approximately 0.66%, and as of May 31, 2025, it was 0.52%. Herriot Tabuteau, the founder and CEO, is the largest individual shareholder, owning 7.35 million shares, representing 14.93% of the company as of a recent report.

Ownership Dynamics of Axsome Therapeutics

The ownership structure of Axsome Therapeutics has evolved significantly since its IPO, with a strong shift towards institutional investors. This indicates confidence in the company's growth and future. Understanding the major shareholders and their holdings is crucial for assessing the company's stability and potential.

• Institutional ownership dominates, holding over 77% of shares as of May 2025.
• Key institutional shareholders include Vanguard Group Inc. and BlackRock, Inc.
• Herriot Tabuteau, the CEO, is the largest individual shareholder.
• The general public and retail investors hold the remaining shares.

Axsome PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

The Board of Directors at Axsome Therapeutics significantly influences the company's strategic direction and governance. Dr. Herriot Tabuteau, the founder, serves as Chief Executive Officer, President, and Chairman of the Board since the company's establishment in January 2012. His expertise in medicine and healthcare finance is vital for strategic planning and operational oversight. Other key independent directors include Susan M. Mahony, Roger A. Jeffs, Mark Coleman (Lead Independent Director), and Mark E. Saad, contributing diverse perspectives to the company's leadership.

As of June 2025, the company had 49,219,312 shares of common stock outstanding. Each holder of common stock is entitled to one vote per share, reflecting a one-share-one-vote structure. At the Annual Meeting of Stockholders on June 6, 2025, approximately 84.04% of the shares were represented, constituting a quorum. The items on the agenda included the election of a Class I director, the approval of the company's 2025 Long-Term Incentive Plan, the ratification of Deloitte & Touche LLP as the independent registered public accounting firm for 2025, and a non-binding advisory vote on executive compensation. This high level of participation indicates strong shareholder engagement.

The structure of Axsome Therapeutics' governance, with its clear voting rights and active shareholder participation, provides a stable environment. The company's leadership, including its board of directors and executives, plays a crucial role in shaping the company's future. Understanding the board's composition and the voting structure is essential for any investor considering Axsome stock or analyzing Axsome ownership. For those interested in a broader view, Competitors Landscape of Axsome provides additional context.

Key Highlights of Axsome Therapeutics' Board and Voting

The board is led by Dr. Herriot Tabuteau, the founder, who holds multiple key positions.

• One-share-one-vote structure ensures fair voting.
• High shareholder participation, with approximately 84% of shares represented at the 2025 Annual Meeting.
• The board includes independent directors with diverse backgrounds.
• Focus on standard governance practices, including director elections and executive compensation votes.

Axsome Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, Axsome Therapeutics has experienced significant developments that have influenced its ownership structure. A pivotal moment was the FDA approval of Auvelity in 2022, followed by a successful launch in 2023. This transition transformed the company from a clinical-stage entity to a commercial biopharmaceutical firm. Auvelity generated $130.1 million in net product revenue in 2023, with total year-to-date net product revenue reaching $270.6 million by Q3 2024. Additionally, the strategic acquisition of Sunosi broadened Axsome's portfolio with an approved, revenue-generating product.

Ownership trends demonstrate a continued increase in institutional ownership. As of May 31, 2025, institutional ownership reached 77.76%, up from 75.40% in April 2025. This trend of increased institutional accumulation is also reflected in the Fund Sentiment Score. Major institutional investors such as Vanguard Group Inc. and BlackRock, Inc. continue to hold substantial stakes. While institutional ownership has generally increased, some investors, such as RTW Investments LP, have recently decreased their holdings.

Insider ownership, though relatively small, has remained fairly stable, with insiders holding approximately 0.66% of shares in April 2025. There is insufficient data to determine if insiders have bought more shares than they have sold in the past three months as of late March 2025. Axsome's market capitalization has grown substantially, increasing from $154.90 million at its IPO in November 2015 to $5.21 billion as of June 13, 2025, representing a compound annual growth rate of 44.41%. Analyst price targets for Axsome Therapeutics as of June 2, 2025, suggest a potential upside, with an average one-year price target of $180.06 per share, indicating confidence in the company's future performance.

Axsome Ownership Trends

Institutional investors are increasing their stakes in Axsome, reflecting confidence. Insider ownership remains stable but is a small percentage. The company's market capitalization has seen significant growth.

Key Shareholders of Axsome

Major institutional investors like Vanguard and BlackRock hold significant positions. These large stakes highlight the interest of institutional investors in Axsome stock. The ownership structure is primarily institutional.

Axsome Therapeutics Financial Performance

Auvelity's launch has been a success, driving revenue growth. The acquisition of Sunosi has diversified the product portfolio. The company's financial performance is improving.

Analyst Outlook for Axsome

Analysts have a positive outlook, with a price target of $180.06 per share. This suggests potential for future stock appreciation. The market anticipates continued growth.

Axsome Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔

Related Blogs